Low-dose radiation, chemo, and immunotherapy before esophageal cancer surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy before surgery for esophageal cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific type of esophageal cancer called squamous cell carcinoma, and it hasn't spread to distant organs.
- You are well enough to have surgery to remove the tumor, and your doctor believes it can be completely removed.
- You are between 18 and 75 years old and able to perform daily activities with little to no help (ECOG score 0-1).
- Your blood counts, liver, kidney, and lung function are within healthy ranges.
- You have not had prior treatment for this cancer, including chemotherapy, radiation, or immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of three medicines (immunotherapy plus two chemotherapy drugs) given before surgery to shrink esophageal cancer. The goal is to make the tumor smaller and easier to remove completely, potentially improving the chance of a cure.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
This study tests a combination of two chemotherapy drugs (paclitaxel and cisplatin) plus an immunotherapy drug (sintilimab) given before surgery for esophageal cancer. The goal is to see if this approach shrinks the tumor and improves outcomes.
This trial tests whether giving a combination of immunotherapy and chemotherapy before surgery can shrink esophageal cancer and improve outcomes. It is designed for patients with early-stage but treatable esophageal squamous cell carcinoma who are candidates for surgery.
This trial tests a chemotherapy combination (nab-paclitaxel plus cisplatin) given before surgery for locally advanced, operable esophageal squamous cell cancer. It aims to shrink the tumor and improve outcomes by treating cancer earlier while it’s still in one region.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.